Drugs Containing Excipient (Inactive Ingredient) ACETYLTRYPTOPHAN, DL-

Generic drugs containing ACETYLTRYPTOPHAN, DL- excipient

Company	Ingredient	NDC	Excipient
GRIFOLS USA LLC	plasma protein fraction (human)	13533-613	ACETYLTRYPTOPHAN, DL-
GRIFOLS USA LLC	albumin (human)	13533-690	ACETYLTRYPTOPHAN, DL-
GRIFOLS USA LLC	albumin (human)	13533-691	ACETYLTRYPTOPHAN, DL-
GRIFOLS USA LLC	albumin (human)	13533-692	ACETYLTRYPTOPHAN, DL-
A-S Medication Solutions	albumin (human)	50090-6320	ACETYLTRYPTOPHAN, DL-

ACETYLTRYPTOPHAN, DL- Market Dynamics, Pharmaceutical Demand, and Financial Trajectory

Last updated: August 5, 2026

DL-acetyltryptophan, usually identified as N-acetyl-DL-tryptophan or acetyltryptophanate, is a specialty pharmaceutical excipient used primarily as a stabilizer in selected plasma-derived products, especially human serum albumin. Its market is small, regulated, and largely captive to a limited number of albumin and biologics manufacturers. Public companies do not generally disclose revenue for the ingredient as a separate product line, so financial analysis relies on downstream albumin demand, supplier economics, regulatory requirements, and substitution risk.

The commercial outlook is stable rather than high-growth. Demand is supported by albumin production, hospital utilization, and continued use of legacy formulations. Growth is constrained by the maturity of the albumin market, the availability of alternative stabilizers, and the limited number of pharmaceutical applications.

What is DL-acetyltryptophan and how is it used in pharmaceuticals?

DL-acetyltryptophan is an acetylated derivative of racemic tryptophan. In pharmaceutical manufacturing, the material is used as an excipient and stabilizer rather than as an active therapeutic ingredient.

Its principal role is associated with protein stabilization. Albumin is susceptible to aggregation, denaturation, and degradation during processing, storage, and heat treatment. Acetyltryptophanate has historically been included in some albumin formulations to help preserve product quality during manufacturing and storage.

Typical pharmaceutical functions include:

• Stabilization of human serum albumin.
• Protection of proteins during pasteurization or heat treatment.
• Reduction of aggregation and loss of protein activity.
• Support for long-term stability in injectable formulations.

Product labels commonly identify the ingredient as acetyltryptophanate or N-acetyl-DL-tryptophan. Albumin products may also contain sodium caprylate, sodium chloride, or other formulation components depending on the manufacturer and concentration. FDA-approved albumin labels from Grifols, CSL Behring, and other manufacturers identify acetyltryptophanate in certain formulations.[1-3]

What is the chemical and regulatory identity of DL-acetyltryptophan?

Attribute	Description
Common name	Acetyltryptophan, DL-
Alternative name	N-acetyl-DL-tryptophan
Pharmaceutical label name	Acetyltryptophanate
Function	Protein stabilizer and excipient
Primary application	Human serum albumin and selected plasma-derived products
Product type	Small-molecule specialty excipient
Market position	Low-volume, high-compliance input
Commercial structure	B2B supply to pharmaceutical manufacturers
Principal regulatory issue	Identity, purity, impurity profile, GMP consistency, and formulation acceptance

What pharmaceutical products contain acetyltryptophanate?

Acetyltryptophanate is associated most strongly with human albumin products. It is not a universal albumin excipient. Formulations differ by manufacturer, concentration, manufacturing process, and regional approval.

Examples of albumin products with labeling that has identified acetyltryptophanate include selected presentations of:

• Albuminar-5 and Albuminar-25.
• Albutein 5% and Albutein 25%.
• Other human albumin products manufactured for the U.S. and international markets.

The ingredient is not present in every albumin product. Some manufacturers use alternative stabilizer systems, including caprylate-based systems. This creates a substitution risk for suppliers of acetyltryptophan because a change in the downstream formulation can eliminate demand without affecting the albumin product category itself.

What formulations are protected by acetyltryptophan?

The formulation value of acetyltryptophan lies in its contribution to a finished protein product, not in ownership of the excipient molecule. A manufacturer may protect an albumin formulation through:

• A composition containing albumin and a defined stabilizer combination.
• A heat-treatment process.
• A method for reducing protein aggregation.
• A specified pH, ionic strength, or excipient concentration.
• A container-closure or storage system.

The excipient itself is an established chemical entity. Its commercial value generally comes from qualification, consistency, regulatory history, and supply reliability rather than molecule-level exclusivity.

How large is the DL-acetyltryptophan pharmaceutical market?

No major pharmaceutical company publicly reports DL-acetyltryptophan revenue as a standalone category. Market research reports generally group it within amino-acid derivatives, pharmaceutical excipients, protein stabilizers, or specialty biochemical ingredients.

The addressable market is constrained by four factors:

1. The ingredient is used in a narrow set of formulations.
2. Albumin production is concentrated among a limited group of plasma-product companies.
3. The quantity used per finished product is small compared with active pharmaceutical ingredients.
4. Formulation substitution can reduce demand even when albumin sales grow.

The most useful market proxy is global human albumin demand. Albumin is used in volume replacement, liver disease, intensive care, surgery, burns, and selected nephrology indications. CSL Behring, Grifols, Takeda, Kedrion, Octapharma, China Biologics, and regional plasma-product manufacturers participate in the broader market.[4-8]

Albumin demand does not translate one-for-one into acetyltryptophan demand. It increases the potential customer base, but actual purchasing depends on the stabilizer system approved in each product.

What is driving demand for DL-acetyltryptophan?

Growth in albumin consumption

Hospital demand for albumin remains the primary commercial driver. Increased plasma collection, expanded fractionation capacity, and higher use in critical care can support demand for albumin-associated excipients.

Growth is strongest in markets where:

• Plasma fractionation capacity is expanding.
• Albumin availability is improving.
• Hospitals are increasing use in cirrhosis, liver transplantation, or critical care.
• Domestic biologics manufacturing is being developed.
• Local regulators accept established albumin formulations.

Regulatory familiarity

An excipient with a long history in approved injectable products has an advantage during formulation development. Manufacturers may prefer a known stabilizer to reduce development and regulatory risk, particularly where the product is based on an established albumin platform.

This advantage is strongest for existing formulations. It is weaker for new products because developers can choose alternative stabilizers before clinical and commercial manufacturing begins.

Supply-chain qualification

Pharmaceutical excipient suppliers must maintain consistent specifications, validated analytical methods, change-control procedures, and documentation. Once a supplier is qualified, the buyer may avoid switching because a change can trigger comparability work, regulatory notification, or process validation.

This creates recurring revenue potential despite low unit volume.

What constrains the financial trajectory of acetyltryptophan?

The financial trajectory is limited by the ingredient's narrow use case.

Mature downstream market

Human albumin is an established plasma-derived product. Demand can grow, but it is unlikely to expand at the rate of newer biologic therapies. The excipient therefore lacks exposure to broad growth categories such as monoclonal antibodies, cell therapy, or messenger RNA products.

Formulation substitution

Alternative stabilizers, including caprylate-based systems, can reduce demand. A supplier cannot assume that albumin-market growth will produce equivalent growth in acetyltryptophan sales.

Low material intensity

The amount of excipient used per vial or bottle is small. Commercial value depends on recurring supply contracts, pharmaceutical-grade processing, and qualification barriers rather than high selling volume.

Customer concentration

The principal customers are plasma fractionators and albumin manufacturers. A supplier losing one qualified customer could experience a disproportionate revenue decline.

Limited pricing power

The material is specialized, but it is not normally the main cost driver in albumin manufacturing. Buyers can exert pricing pressure if more than one qualified source exists. Pricing power is stronger when the material is difficult to replace without regulatory or validation work.

How does DL-acetyltryptophan compare with alternative albumin stabilizers?

Factor	DL-acetyltryptophan	Sodium caprylate and related stabilizers
Main use	Stabilizer in selected albumin formulations	Stabilizer in albumin and protein products
Regulatory history	Established in legacy albumin products	Established in multiple albumin systems
Switching burden	Requires formulation and comparability assessment	Requires formulation and comparability assessment
Commercial risk	Demand can fall if customers reformulate	Similar substitution risk
Differentiation	Purity, consistency, documentation, supply reliability	Same factors
Growth exposure	Closely tied to specific albumin formulations	Broader where used across multiple products
Patent position	Limited molecule-level exclusivity	Limited molecule-level exclusivity

The competitive question is not whether acetyltryptophan replaces albumin. It is whether a particular albumin manufacturer continues using an acetyltryptophan-containing formulation.

What patents protect DL-acetyltryptophan?

No meaningful current composition-of-matter exclusivity should be expected for DL-acetyltryptophan as a mature chemical excipient. Any original molecule-level patents would be expired or commercially irrelevant in the current market.

Potentially relevant intellectual-property categories include:

• Albumin compositions containing acetyltryptophanate.
• Stabilized protein formulations.
• Heat-treatment processes for plasma-derived products.
• Methods for reducing aggregation or oxidation.
• Manufacturing processes for acetyltryptophan with controlled impurity levels.
• Specific combinations of albumin, caprylate, acetyltryptophanate, and other excipients.

These rights generally protect a finished formulation or manufacturing process, not the ordinary purchase and use of the excipient as a commodity ingredient.

Are formulation patents commercially important?

They can be important for a specific albumin product, but their effect on the excipient market is indirect. A formulation patent may limit a competitor's ability to copy a product, yet it does not necessarily give the excipient supplier control over the market.

The main commercial barriers are usually:

• FDA approval of the finished albumin product.
• Plasma sourcing and fractionation capability.
• Manufacturing validation.
• Product-specific quality systems.
• Regulatory approval of formulation changes.
• Customer qualification of the excipient supplier.

What is the FDA regulatory status of acetyltryptophan?

DL-acetyltryptophan is used as an excipient in FDA-regulated products, but it is not an independently marketed active pharmaceutical product in this context. Its regulatory status depends on the finished product and route of administration.

For injectable use, manufacturers must establish:

• Chemical identity and assay.
• Impurity limits.
• Residual solvent controls.
• Microbial and endotoxin controls where applicable.
• Stability data.
• Supplier qualification.
• Compliance with current good manufacturing practice.
• Suitability for the specific albumin formulation.

The FDA-approved product label, rather than the excipient alone, is the key regulatory document. Albumin labels identify inactive ingredients and concentration-specific formulation details.[1-3]

What is the Orange Book status of DL-acetyltryptophan?

DL-acetyltryptophan does not have an Orange Book listing as an independently approved drug. The Orange Book covers approved drug products and their patent or exclusivity information, not ordinary excipient supply.

As a result:

• There is no standalone Orange Book patent listing for the excipient.
• Paragraph IV certification does not apply to the excipient itself.
• Generic-drug litigation is not the normal competitive mechanism.
• Patent disputes would more likely involve a finished albumin product or manufacturing process.

When does acetyltryptophan lose exclusivity?

The excipient has no practical modern exclusivity period comparable to a new chemical entity. Commercial exclusivity is instead created by customer qualification, formulation history, supply contracts, and manufacturing know-how.

Relevant exclusivity categories are:

Exclusivity type	Applicability
New chemical entity exclusivity	Not applicable
Standalone drug patent term	Not applicable to ordinary excipient supply
Orange Book listing	Not applicable
Paragraph IV challenge	Not applicable
Biologic exclusivity	Applies to the finished biologic, not the excipient
Formulation patent	Possible for a finished albumin product
Process patent	Possible, subject to claim scope and expiration
Supplier qualification	Commercial barrier, not statutory exclusivity

Which companies are challenging or competing with acetyltryptophan suppliers?

There is no conventional branded-drug challenger market. Competition occurs among pharmaceutical-grade chemical suppliers and among albumin manufacturers selecting alternative stabilizer systems.

The relevant competitive groups are:

• Specialty amino-acid and biochemical manufacturers.
• GMP excipient producers.
• Chemical companies with pharmaceutical documentation systems.
• Albumin manufacturers using alternative stabilizers.
• Vertically integrated plasma fractionators that control formulation and procurement internally.

Public disclosures rarely identify the supplier of acetyltryptophan used in a finished albumin product. Supplier identity is often confidential and may change after regulatory review and qualification.

What patent litigation affects DL-acetyltryptophan?

No major standalone patent-litigation pattern is associated with DL-acetyltryptophan as an excipient. Any relevant dispute would more likely involve:

• A branded albumin product.
• A biosimilar or follow-on plasma-derived product.
• A protein-stabilization formulation.
• A plasma fractionation or heat-treatment method.
• A supplier's manufacturing process or impurity-control technology.

Biosimilar litigation is also not directly applicable to the excipient. A biosimilar or follow-on biologic manufacturer may use the same or a different stabilizer, but any dispute would concern the biologic product, regulatory pathway, or manufacturing process.

What generic entry risks exist for albumin products using acetyltryptophan?

Generic entry risk is limited by the complexity of plasma-derived products. Albumin is not a simple small-molecule tablet. A competitor must address:

• Plasma sourcing.
• Viral clearance.
• Fractionation.
• Protein characterization.
• Aggregation and degradation controls.
• Sterility and container closure.
• Demonstration of product comparability.
• Manufacturing scale and regulatory inspection.

The risk to acetyltryptophan demand comes from two different entry routes:

1. A competing albumin product uses the same stabilizer, preserving excipient demand while adding a customer.
2. A competing albumin product uses a different stabilizer, creating no new demand and potentially increasing substitution pressure.

How does geographic coverage affect the market?

Demand is concentrated in countries with significant plasma fractionation and albumin manufacturing capacity. The United States, Europe, China, Japan, South Korea, Australia, and selected Middle Eastern markets are important regulatory or commercial regions.

Geographic barriers include:

• Different pharmacopeial requirements.
• Country-specific supplier qualification.
• Local GMP inspection expectations.
• Import controls for pharmaceutical raw materials.
• Regional albumin formulation differences.
• Different acceptance of excipient specifications.

A supplier with U.S. FDA, European Pharmacopoeia, and Japanese regulatory documentation can address more customers than a supplier qualified only for industrial or research-grade material.

What manufacturing and IP barriers protect acetyltryptophan suppliers?

The molecule is not inherently difficult to make at laboratory scale. The barrier is pharmaceutical execution.

A commercially credible supplier must control:

• Stereochemical composition of the DL material.
• Residual starting materials.
• Related acetylated or oxidized impurities.
• Heavy metals and elemental impurities.
• Residual solvents.
• Particle properties and physical form.
• Batch-to-batch consistency.
• Packaging and transport stability.
• Change-control procedures.
• Audit readiness and regulatory documentation.

Manufacturing know-how and customer qualification can therefore provide more practical protection than patents. A supplier with an established dossier and a long quality history may retain business even when competing chemical producers can synthesize the same compound.

What is the financial outlook for DL-acetyltryptophan?

The base-case outlook is low-single-digit market growth, closely linked to albumin production and hospital demand rather than independent innovation. The revenue profile should remain recurring but concentrated.

Financial driver	Expected effect
Higher albumin production	Positive
Expansion of plasma fractionation	Positive
New albumin customers using the excipient	Positive
Reformulation toward caprylate or other stabilizers	Negative
Supplier qualification by additional manufacturers	Positive
Loss of one major customer	Materially negative
Commodity-grade competition	Negative for price
GMP scarcity and supply disruption	Positive for qualified suppliers, negative for buyers
New biologic applications	Limited near-term contribution

The most attractive commercial position is a qualified GMP supplier with multiple albumin customers, regulatory support in major jurisdictions, and the ability to supply related protein-stabilization excipients. A single-customer supplier faces a weaker risk-adjusted outlook.

Key Takeaways

• DL-acetyltryptophan is a specialty pharmaceutical excipient used mainly as acetyltryptophanate in selected human albumin formulations.
• Its market is small, recurring, and dependent on a limited number of plasma-derived product manufacturers.
• Public companies do not normally disclose standalone revenue for the ingredient.
• Albumin demand is the principal market proxy, but albumin growth does not guarantee equivalent excipient growth.
• Formulation substitution, especially toward caprylate-based systems, is the main commercial risk.
• The molecule has no meaningful current standalone drug exclusivity or Orange Book position.
• Paragraph IV, generic-drug, and biosimilar challenges apply to finished products, not the excipient itself.
• The strongest commercial barriers are GMP quality, regulatory documentation, supplier qualification, and customer switching costs.
• The financial outlook is stable to modestly growing, with substantial customer-concentration risk.

FAQs

Is DL-acetyltryptophan the same as acetyltryptophanate?

They are closely related naming conventions. Pharmaceutical labels commonly use acetyltryptophanate for the excipient form used in finished albumin products, while chemical suppliers may use N-acetyl-DL-tryptophan or DL-acetyltryptophan.

Is acetyltryptophan used in vaccines?

It is not a universal vaccine excipient. Its established commercial association is with selected plasma-derived protein products, especially human albumin. Product-specific regulatory filings determine whether it is present.

Can a pharmaceutical company switch away from acetyltryptophan without a new clinical trial?

A formulation change normally requires regulatory assessment, stability work, comparability data, and process validation. Whether clinical data are required depends on the product, the extent of the change, and the applicable regulatory pathway.

Is DL-acetyltryptophan listed in the FDA Inactive Ingredient Database?

The relevant regulatory assessment is route- and product-specific. FDA-approved product labeling provides the most direct evidence of use in a particular injectable formulation.

Who benefits financially if albumin demand increases?

Qualified manufacturers of albumin, plasma-derived product suppliers, and validated excipient suppliers can benefit. The benefit to acetyltryptophan suppliers depends on whether incremental albumin capacity uses an acetyltryptophan-containing formulation.

References

1. U.S. Food and Drug Administration. (n.d.). Albuminar-25 prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Albutein 5% and Albutein 25% prescribing information.
3. U.S. Food and Drug Administration. (n.d.). Albumin human product labeling and biologics license information.
4. CSL Behring. (2023). Annual report 2023.
5. Grifols, S.A. (2023). Annual report 2023.
6. Takeda Pharmaceutical Company Limited. (2024). Annual report 2024.
7. European Medicines Agency. (n.d.). Human albumin: Product information and regulatory documentation.
8. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.